Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
16-week open-label switch study from quetiapine to ziprasidone in schizophrenia or schizoaffective disorder
2006-003475-13Phase 4Completed
- Sponsor
- Pfizer
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ziprasidone in schizophrenia and schizoaffective disorder, sponsored by Pfizer. Primary endpoint: Change in body weight from baseline to Week 16. Started Sep 2006; status: completed.
02
Drugs
ziprasidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on 2006-003475-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003475-13.